
Terry D Crawford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9413836/publications.pdf Version: 2024-02-01



TEDDY D CDAMEODD

#	Article	IF	CITATIONS
1	A Multifaceted Hit-Finding Approach Reveals Novel LC3 Family Ligands. Biochemistry, 2023, 62, 633-644.	1.2	8
2	GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like. Journal of Medicinal Chemistry, 2018, 61, 9301-9315.	2.9	11
3	GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2). ACS Medicinal Chemistry Letters, 2017, 8, 737-741.	1.3	18
4	Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3534-3541.	1.0	28
5	GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). Journal of Medicinal Chemistry, 2017, 60, 9162-9183.	2.9	77
6	A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 10151-10171.	2.9	21
7	Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. Journal of Medicinal Chemistry, 2016, 59, 5391-5402.	2.9	95
8	Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. Journal of Biological Chemistry, 2016, 291, 13014-13027.	1.6	58
9	Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. Journal of Medicinal Chemistry, 2016, 59, 10549-10563.	2.9	69
10	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). ACS Medicinal Chemistry Letters, 2016, 7, 531-536.	1.3	87
11	Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1271-1298.	2.9	171
12	Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4546-4552.	1.0	21